Sign up to save your podcasts
Or
Share Updates in the Diagnosis and Management of CKD: The Role of Mineralocorticoid Antagonists in Evolving the Therapeutic Landscape - Podcast #2
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Updates in the Diagnosis and Management of CKD: The Role of Mineralocorticoid Antagonists in Evolving the Therapeutic Landscape - Podcast #2
In the first podcast of this series Nephrology experts Christos Argyropoulos, MD, PhD, FASN and Edgar Lerma, MD discussed the development and use of mineralocorticoid antagonists for the treatment of chronic kidney disease (CKD). In this next episode, they further that discussion by diving into the burdens and complex pathophysiology of CKD, followed by the complexities and considerations for screening and diagnosis. They then close out the conversation with a brief review of the emerging non-steroidal mineralocorticoid antagonists for CKD.
For more information and to claim credit visit, https://integrityce.com/ckdpodcast2
View the figures referenced during this podcast here: https://integrityce.com/wp-content/uploads/2021/11/i782-8_podcast-2_figures.pdf
Integrity Continuing Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Supported by an educational grant from Bayer HealthCare Pharmaceuticals, Inc.
You can listen the first episode of this podcast at, https://integrityce.com/ckdpodcast1
View all episodes
By Integrity CEIn the first podcast of this series Nephrology experts Christos Argyropoulos, MD, PhD, FASN and Edgar Lerma, MD discussed the development and use of mineralocorticoid antagonists for the treatment of chronic kidney disease (CKD). In this next episode, they further that discussion by diving into the burdens and complex pathophysiology of CKD, followed by the complexities and considerations for screening and diagnosis. They then close out the conversation with a brief review of the emerging non-steroidal mineralocorticoid antagonists for CKD.
For more information and to claim credit visit, https://integrityce.com/ckdpodcast2
View the figures referenced during this podcast here: https://integrityce.com/wp-content/uploads/2021/11/i782-8_podcast-2_figures.pdf
Integrity Continuing Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Supported by an educational grant from Bayer HealthCare Pharmaceuticals, Inc.
You can listen the first episode of this podcast at, https://integrityce.com/ckdpodcast1